The Foundation Fighting Blindness is the world’s leading private funding source for research to treat, prevent, and cure retinal degenerative diseases. Many of the trials listed below were made possible by Foundation support.
GENE THERAPIES (GENE TARGET) |
PROGRESS |
|
Achromatopsia (CNGB3) – AGTC |
Phase 1/2 |
|
Achromatopsia (CNGB3) – MeiraGTx / Janssen |
Phase 1/2 |
|
Achromatopsia (CNGA3) – AGTC |
Phase 1/2 |
|
Achromatopsia (CNGA3) – Tubingen Hosp |
Phase 1/2 |
|
AMD-dry – Gyroscope |
Phase 2 |
|
Choroideremia (REP1) – 4DMT |
Phase 1/2 |
|
Choroideremia (REP1) – Spark |
Phase 1/2 |
|
Choroideremia (REP1) – Tubingen Hosp |
Phase 2 |
|
LCA (GUCY2D) – Atsena |
Phase 1/2 |
|
LCA (CEP290, CRISPR) – Editas |
Phase 1/2 |
|
LCA and RP (RPE65) – MeiraGTx / Janssen |
Phase 1/2 |
|
RP (PDE6B) – Coave |
Phase 1/2 |
|
RP (RLBP1) – Novartis |
Phase 1/2 |
|
RP (PDE6A) – Tubingen Hosp |
Phase 1/2 |
|
Retinoschisis (RS1) – NEI |
Phase 1/2 |
|
X-linked RP (RPGR) – AGTC |
Phase 1/2 |
|
X-linked RP (RPGR) – MeiraGTx / Janssen |
Phase 1/2 |
|
X-linked RP (RPGR) – 4DMT |
Phase 1/2 |
|
|
|
RNA/OTHER (MECHANISM) |
PROGRESS |
|
AMD-dry (CB inhibitor) – Ionis |
Phase 2 |
|
AMD-dry (C5 inhibitor) – Iveric bio |
Phase 2 |
|
LCA (CEP290, AON) – ProQR |
Phase 2/3 |
|
RP (RHO, AON) – ProQR |
Phase 1/2 |
|
RP, Usher, others (optogenetic) – Allergan |
Phase 1/2 |
|
RP, Usher, others (optogenetic) – Bionic Sight |
Phase 1/2 |
|
RP, Usher, others (optogenetic) – GenSight |
Phase 1/2 |
|
RP, Usher, others (optogenetic) – Nanoscope |
Phase 2 |
|
Usher syndrome 2A (AON) – ProQR |
Phase 2/3 |
|
|
|
CELL-BASED THERAPIES (CELL TYPE) |
PROGRESS |
|
AMD-dry (RPE) – Astellas |
Phase 1/2 |
|
AMD-dry (RPE) – Cell Cure |
Phase 1/2 |
|
AMD-dry (RPE from iPSC) – NEI |
Phase 1/2 |
|
AMD-dry (RPE on scaffold) – Regen Patch |
Phase 1/2 |
|
RP, Usher (retinal progenitors) – jCyte |
Phase 2b |
|
RP, Usher (retinal progenitors) – ReNeuron |
Phase 2 |
|
Stargardt (RPE) – Astellas |
Phase 1/2 |
|
|
|
SMALL MOLECULES (MECHANISM) |
PROGRESS |
|
AMD-dry (C3 inhibitor) – Apellis |
Phase 3 |
|
RP (NAC-anti-oxidant) – Johns Hopkins |
Phase 2 |
|
Stargardt disease (emixustat) – Acucela |
Phase 3 |
|
Stargardt disease (deuterated vit A) – Alkeus |
Phase 2 |
|
Stargardt disease (C5 inhibitor) – IVERIC bio |
Phase 2 |
|
Stargardt disease (anti-RBP4) – Belite Bio |
Phase 1 |
|
Stargardt disease (anti-RBP4) – Stargazer |
Phase 2 |
|
Stargardt disease (metformin) – NEI |
Phase 1/2 |
|
Usher syndrome (NACA-anti-oxidant) – Nacuity |
Phase 1/2 |
Information current as of January 2022.
